Last reviewed · How we verify
LTX-315
At a glance
| Generic name | LTX-315 |
|---|---|
| Also known as | Arm B (Protocol version 6), GV-1001 |
| Sponsor | Lytix Biopharma AS |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04) (PHASE2)
- Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma (PHASE2)
- NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma (PHASE2)
- LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab (PHASE1)
- Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour (PHASE1)
- A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LTX-315 CI brief — competitive landscape report
- LTX-315 updates RSS · CI watch RSS
- Lytix Biopharma AS portfolio CI